Cannabinoids as gastrointestinal anti-inflammatory drugs.

Neurogastroenterol Motil. 2017 Mar;29(3). doi: 10.1111/nmo.13038.

Abstract

pm-2-site-207In this mini-review, we focus on the potential of the endocannabinoid system as a target for novel therapies to treat gastrointestinal (GI) inflammation. We discuss the organization of the endocannabinoid signaling and present possible pharmacological sites in the endocannabinoid system. We also refer to recent clinical findings in the field. Finally, we point at the potential use of cannabinoids at low, non-psychoactive doses to counteract non-inflammatory pathological events in the GI tract, like chemotherapy-induced diarrhea, as evidenced by Abalo et al. in the rat model.

KEYWORDS:

endocannabinoid metabolism; gastrointestinal tract; inflammation; “classical” and “non-classical” cannabinoid receptors

PMID: 28239924

 

DOI: 10.1111/nmo.13038
[PubMed – in process]

Publication Types

Publication Types

twin memes II

Tags: , , ,